This company has been marked as potentially delisted and may not be actively trading. BeiGene (BGNE) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Wang Xiaodong verkauft BeiGene-Aktien im Wert von 10,1 Mio. US-DollarApril 16, 2025 | de.investing.comRBC Capital setzt BeiGene-Aktie auf "Outperform" mit Kursziel von 312 US-DollarApril 7, 2025 | de.investing.comBeigenes Präsident Wu Xiaobin verkauft Aktien im Wert von 14,6 Millionen US-DollarApril 3, 2025 | de.investing.comBeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung CancerMarch 31, 2025 | businesswire.comWang Xiaodong, Direktor bei Beigene, verkauft Aktien im Wert von 10,9 Millionen US-DollarMarch 21, 2025 | de.investing.comBeiGenes Wu Xiaobin erwartet 1,06 Millionen US-Dollar aus RMB-AktienverkaufMarch 18, 2025 | de.investing.comBernstein erhöht Kursziel für BeiGene-Aktie auf 259 US-DollarMarch 13, 2025 | de.investing.comBeiGene-CEO John Oyler verkauft Aktien im Wert von 10 Millionen US-DollarMarch 12, 2025 | de.investing.comBeigene-CEO John Oyler verkauft Aktien im Wert von 10,39 Millionen US-DollarMarch 8, 2025 | de.investing.comBeigene-CEO John Oyler verkauft Aktien im Wert von 14,6 Millionen US-DollarMarch 8, 2025 | de.investing.comBeigene-Vorstand Wang Xiaodong verkauft Aktien im Wert von über 2 Millionen US-DollarMarch 6, 2025 | de.investing.comBeigene-Präsident verkauft wirtschaftliches Interesse an RMB-Aktien für 1,16 Millionen US-DollarMarch 4, 2025 | de.investing.comBeiGene Vorstand verkauft American Depositary Shares im Wert von 331.375 US-DollarMarch 4, 2025 | de.investing.comJPMorgan hält an Overweight-Rating für BeiGene-Aktie fest, Kursziel 311 US-DollarMarch 4, 2025 | de.investing.comBeiGene announces FDA approval of Tevimbra/chemotherapy combinationMarch 4, 2025 | markets.businessinsider.comChina-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal CancerMarch 4, 2025 | benzinga.comBofA hebt BeiGene-Aktienrating an und erhöht Kursziel auf 320 US-DollarMarch 3, 2025 | de.investing.comBeiGene, Ltd. Announces Board of Directors and Committee RolesMarch 2, 2025 | tipranks.comBeiGene, Ltd. Files Amended Annual Report with SECMarch 2, 2025 | tipranks.comIs BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?March 1, 2025 | msn.comBeiGene: Q4 Results Impress With Positive Earnings Expected In 2025February 28, 2025 | seekingalpha.comTD Cowen erhöht Kursziel für BeiGene-Aktie auf 334 US-DollarFebruary 27, 2025 | de.investing.comKursziel für BeiGene-Aktie auf 308 US-Dollar angehoben nach starken JahresergebnissenFebruary 27, 2025 | de.investing.comBeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesFebruary 27, 2025 | businesswire.comBeigenes globaler F&E-Leiter veräußert Aktien im Wert von 1,29 Mio. US-DollarFebruary 26, 2025 | de.investing.comBeiGene: Leitender Vizepräsident verkauft Aktien im Wert von 310.169 US-DollarFebruary 26, 2025 | de.investing.comBeiGene-Aktie erreicht 52-Wochen-Hoch von 258,66 US-DollarFebruary 21, 2025 | de.investing.comBeiGene-Präsident verkauft Unternehmensaktien im Wert von 12,5 Millionen US-DollarFebruary 21, 2025 | de.investing.comBeigene: Wang Xiaodong veräußert Aktien im Wert von 9,4 Millionen US-DollarFebruary 7, 2025 | de.investing.comBeiGene Schedules EGM for Strategic Corporate ChangesJanuary 17, 2025 | tipranks.comBeiGene Projects Positive Operating Income by 2025January 13, 2025 | tipranks.comBeigene-Direktor Wang Xiaodong veräußert Aktien im Wert von 7,37 Millionen US-DollarJanuary 9, 2025 | de.investing.comBeiGene, Ltd.: TEVIMBRA erhält US-Marktzulassung für die Erstlinienbehandlung von Magen- und GEJ-Tumoren in Kombination mit ChemotherapieDecember 30, 2024 | finanznachrichten.deBeiGene Announces FDA Approval Of TEVIMBRA - Quick FactsDecember 27, 2024 | markets.businessinsider.comBeiGene Secures FDA Approval for Stomach Cancer DrugDecember 27, 2024 | msn.comBeiGene announces FDA approval of TevimbraDecember 27, 2024 | markets.businessinsider.comBeiGene wins FDA nod for Tevimbra in gastric cancerDecember 27, 2024 | msn.comTEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyDecember 27, 2024 | businesswire.comBeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of "Moderate Buy" from AnalystsBeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy rDecember 25, 2024 | marketbeat.comWith 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big gunsDecember 24, 2024 | finance.yahoo.comBeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23, 2024 | uk.finance.yahoo.comBeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23, 2024 | businesswire.comBeiGene-Aktien erhalten erneut Kaufempfehlung aufgrund robuster Onkologie-PipelineDecember 18, 2024 | de.investing.comBeiGene’s Strategic Advancements and Promising Clinical Developments Justify Buy RatingDecember 18, 2024 | markets.businessinsider.comBeiGene (BGNE) Gets a Buy from TD CowenDecember 18, 2024 | markets.businessinsider.comStifel Financial Corp Sells 4,366 Shares of BeiGene, Ltd. (NASDAQ:BGNE)Stifel Financial Corp lessened its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 25.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,807 shares of the company's stock after sellingDecember 18, 2024 | marketbeat.comBeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust FinancialsDecember 17, 2024 | markets.businessinsider.comPublic Employees Retirement System of Ohio Reduces Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)Public Employees Retirement System of Ohio reduced its position in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 73.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,917 shares of the company's stoDecember 17, 2024 | marketbeat.comBeiGene, Ltd. (NASDAQ:BGNE) Sees Significant Increase in Short InterestBeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 1,330,000 shares, a growth of 33.1% from the November 15th total of 999,400 shares. Based on an average daily volume of 367,900 shares, the short-interest ratio is presently 3.6 days.December 14, 2024 | marketbeat.comInsider Selling: BeiGene, Ltd. (NASDAQ:BGNE) Insider Sells 41,760 Shares of StockDecember 13, 2024 | insidertrades.com Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address BGNE Media Mentions By Week BGNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BGNE News Sentiment▼0.000.72▲Average Medical News Sentiment BGNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BGNE Articles This Week▼05▲BGNE Articles Average Week Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TAK News Today ARGX News Today BNTX News Today ONC News Today SMMT News Today TEVA News Today ITCI News Today GMAB News Today RDY News Today ASND News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BGNE) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTop Picks for Trump’s Pro-Crypto AmericaJust Announced: What Trump’s Move Means for Crypto—Join Now 27 top names reveal urgent insights as Bitcoin ...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeiGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
